Quinone-Derived Compounds for Low-Toxicity Leishmania Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cutaneous leishmaniasis, such as pentavalent antimony salts and miltefosine, suffer from high toxicity, resistance, and require parenteral administration, leading to low patient compliance and high costs, while effective topical alternatives with quinone nucleus molecules have not been adequately developed.
Innovation Solution
Development of quinone-derived compounds with specific structural variations (R1, R2, and R3) that exhibit low toxicity and high efficacy against Leishmania spp., synthesized through methods A and B, achieving IC50 values less than 1 μg/ml, and formulated into pharmaceutical compositions for topical or oral use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pentavalent antimony salts or miltefosine are used for treatment, then leishmanicidal activity is achieved, but toxicity increases and patient compliance decreases due to parenteral administration requirement
Solution Approach 1:
The patent modifies the chemical structure of quinone compounds by changing parameters such as substituting different alkyl groups (cyclopentyl, cycloheptyl, 3-methyl-pentyl) at positions R1, R2, and R3 to optimize the balance between leishmanicidal activity and toxicity. This structural parameter optimization enables the compound to achieve effective anti-Leishmania activity while reducing harmful effects on host cells.
Solution Approach 2:
The patent creates synthetic copies of natural quinone structures with modified side chains to replicate and enhance the therapeutic effect while reducing toxicity. The synthesized compounds mimic the core quinone nucleus of natural products but with optimized substituent groups that improve the therapeutic index.
2Adaptability or versatility
If miltefosine is used as second-line treatment, then alternative therapy is provided, but treatment cost and duration increase
Solution Approach 1:
The patent optimizes pharmacokinetic parameters of the quinone derivatives to achieve rapid and effective parasite killing, thereby reducing treatment duration. The structural modifications improve cellular uptake and intracellular concentration of the active compound, leading to faster therapeutic effect and shorter treatment courses compared to miltefosine.
3Ease of operation
If existing topical preparations (paromomycin, amphotericin B, miltefosine) are developed, then topical application is enabled, but sufficient efficacy is not achieved
Solution Approach 1:
The patent designs composite molecular structures combining the quinone nucleus with specific hydrophobic side chains (cycloalkyl groups) to create amphiphilic compounds that can effectively partition into the lipid-rich environment of the parasitic membrane. This composite structure enables both topical applicability and high efficacy by simultaneously achieving good skin penetration and potent antiparasitic activity.
Solution Approach 2:
The patent introduces specific functional groups at particular positions of the quinone molecule to create local regions with different properties. The cycloalkyl substituents at R1, R2, and R3 positions provide localized hydrophobic character that enhances membrane interaction and parasite killing efficiency, while the quinone core maintains the necessary reactivity for topical application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthesized quinone-derived compounds demonstrate significant leishmanicidal activity with IC50 values below 1 μg/ml, showing improved efficacy and reduced toxicity compared to miltefosine, with selectivity indices indicating low harm to host cells.
Implementation Method 1
which often acts as a DNA intercalating agent, a biomolecule alkylating agent, and/or a reactive oxygen species generator
Data Source
AI summary
The present invention relates to quinone-derived compounds with leishmanicidal activity and to the use of same in the pharmaceutical industry, specifically in the field of parasitic diseases. The invention relates specifically to a compound of formula (I), the isomeric forms thereof and the salts of same, wherein R1 and R3 are hydrogen and R2 is selected from the list consisting of cyclopentyl, cycloheptyl, 3-methyl-pentyl and adamantane, or wherein R1 and R2 are hydrogen and R3 is selected from the list consisting of cyclopentyl, cyclohexyl and cycloheptyl.